Items in AFP with MESH term: Bone Density

Pages: Previous 1 2

ACOG Releases Guidelines for Clinical Management of Osteoporosis - Practice Guidelines


Teriparatide (Forteo) for Osteoporosis - STEPS


Calcium Supplementation in Postmenopausal Women - Cochrane for Clinicians


Osteoporosis Management: Out of Subspecialty Practice and into Primary Care - Editorials


Predicting Hip Fracture Risk in Older Women - Point-of-Care Guides


Update on Subclinical Hyperthyroidism - Article

ABSTRACT: Subclinical hyperthyroidism is defined by low or undetectable serum thyroid-stimulating hormone levels, with normal free thyroxine and total or free triiodothyronine levels. It can be caused by increased endogenous production of thyroid hormone (as in Graves disease or toxic nodular goiter), administration of thyroid hormone for treatment of malignant thyroid disease, or unintentional excessive thyroid hormone therapy. The rate of progression to overt hyperthyroidism is higher in persons who have suppressed thyroid-stimulating hormone levels compared with those who have low but detectable levels. Subclinical hyperthyroidism is associated with an increased risk of atrial fibrillation in older adults, and with decreased bone mineral density in postmenopausal women; however, the effectiveness of treatment in preventing these conditions is unknown. There is lesser-quality evidence suggesting an association between subclinical hyperthyroidism and other cardiovascular effects, including increased heart rate and left ventricular mass, and increased bone turnover markers. Possible associations between subclinical hyperthyroidism and quality of life parameters, cognition, and increased mortality rates are controversial. Prospective randomized con- trolled trials are needed to address the effects of early treatment on potential morbidities to help determine whether screening should be recommended in the asymptomatic general population.


Screening for Osteoporosis: Recommendation Statement - U.S. Preventive Services Task Force


Screening for Osteoporosis - Putting Prevention into Practice


NOF Urges Bone Density Tests for Certain Postmenopausal Women and All Women Over Age 65 - Special Medical Reports


Pages: Previous 1 2


Information From Industry